A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity
Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR
Oral BPC-157 is designed to act locally within the gastrointestinal tract, which makes it more appropriate for gut applications than systemic injection
Notably, Gln deprivation significantly reduced the expression of CCNB1, CDK1 and p-CDK1 in HCC and PCa cells (Fig
Ti Sao N Li Quan Trng Vi C Th
Research context: These statements reflect the brand's description and are not clinical findings for the finished product